RFK Jr. wants Americans to use peptides that were banned over safety risks
Ars Technica • • business
Key Points:
- Robert F. Kennedy Jr. is advocating for the FDA to lift restrictions on over a dozen injectable peptide treatments that currently lack robust efficacy data and were previously banned due to safety concerns.
- These peptides, popularized by wellness influencers and biohackers for unproven claims such as reversing aging and treating diseases, were reclassified by the FDA in 2023 to restrict their production by compounding pharmacies.
- The FDA is reportedly moving to allow compounding pharmacies to produce 14 restricted peptides, including BPC-157, CJC-1295, and Ipamorelin, despite internal reservations about safety and the political implications of the decision.
- Experts warn that there is a significant lack of randomized controlled trials supporting these peptides' benefits, and they highlight risks such as impurities, inconsistent dosing, hormonal imbalances, and potential cancer stimulation.
- Critics, including The Washington Post editorial board and medical experts, have condemned Kennedy's push as irresponsible and potentially dangerous due to the minimal scientific evidence and known safety hazards associated with these treatments.
